We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Vaxart Inc | NASDAQ:VXRT | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.0516 | 7.84% | 0.71 | 0.71 | 0.74 | 0.7097 | 0.6603 | 0.6985 | 1,321,643 | 01:00:00 |
From Apr 2019 to Apr 2024
Australian drug development company Biota Holdings Ltd. (BTA.AU) said Monday it plans to merge with Nabi Biopharmaceuticals (NABI) to form a combined company to be listed on Nasdaq.
Biota said in a statement the move to the U.S. was designed to achieve better value recognition and liquidity through a stronger U.S. shareholder base.
"We believe this is a necessary step to increase our options for the development and commercialization of our product portfolio and will ultimately improve the recognition of the underlying value of our product portfolio for our shareholders," said Biota Chairman Jim Fox.
Biota develops anti influenza drugs such as Relenza, which is marketed by GlaxoSmithKline PLC.
Under the merger, Nabi will acquire all the shares in Biota for new shares in the name of Biota Pharmaceuticals, a Nasdaq listed company. Biota shareholders will own about 74% of Biota Pharmaceuticals and Nabi shareholders will own about 26% of the company.
Nabi plans to return US$54 million to existing shareholders.
-By Gavin Lower, Dow Jones Newswires; 61-3-9292-2095; gavin.lower@dowjones.com
1 Year Vaxart Chart |
1 Month Vaxart Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
